NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
22.09
+0.44 (2.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
NovoCure Employees
NovoCure had 1,453 employees as of December 31, 2023. The number of employees increased by 133 or 10.08% compared to the previous year.
Employees
1,453
Change (1Y)
133
Growth (1Y)
10.08%
Revenue / Employee
$397,617
Profits / Employee
-$103,086
Market Cap
2.39B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
NVCR News
- 4 weeks ago - Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Business Wire
- 5 weeks ago - Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update - Business Wire
- 7 weeks ago - Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha
- 2 months ago - Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields - Seeking Alpha
- 2 months ago - NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients - Benzinga
- 2 months ago - Novocure's pancreatic cancer treatment meets main goal in late-stage study - Reuters
- 2 months ago - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire